(Q36641423)

English

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party

scientific article published on February 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

van Herpen CM

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jansen RL

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Kruit WH

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Hoekman K

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Groenewegen G

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Osanto S

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

De Mulder PH

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 February 2000

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

82

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

772-776

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

https://scigraph.springernature.com/pub.10.1054/bjoc.1999.0997

0 references

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

30 September 2017

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

28 June 2018

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

28 June 2018

The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

28 June 2018

5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

28 June 2018

A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

28 June 2018

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

20 September 2018

European studies of interleukin-2 in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374413

21 October 2018

Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/10732744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.1999.0997

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36641423&oldid=1642891097"